Cardiac Science raises $8.7 million:
This article was originally published in Clinica
Cardiac Science has raised $8.7 million through a private placement. The Irvine, California-based company claims it has developed the only external defibrillator that continuously monitors in-hospital patients at risk of sudden cardiac arrest. If necessary, the product administers a shock within seconds, without the aid of hospital staff. The company will use the proceeds for the global marketing of its Powerheart ECD, which it plans to launch this quarter.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.